Serious adverse events · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Adverse effects: dry mouth · Adults with overactive bladder (OAB)
Anticholinergics may leads to higher adverse events: dry mouth compared with placebo (low certainty).
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in adverse events compared with non‐active comparators (low certainty).
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with primary progressive aphasia (PPA)
1 finding from 1 review
Adverse events · chronic pain (excluding headache) in adults
1 finding from 1 review
Adverse events · People aged 12 years and over with painful TMD lasting 3 months or longer
1 finding from 1 review
Adverse events · adults and children with CF
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in adverse events compared with placebo with anti‐TNF (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review